Shares of Marina Biotech, Inc. (OTCMKTS:MRNA) have been assigned a consensus rating of “Buy” from the ten research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $27.43.
A number of equities research analysts recently commented on MRNA shares. Chardan Capital started coverage on shares of Marina Biotech in a research report on Friday, April 5th. They issued a “buy” rating and a $40.00 price objective for the company. Zacks Investment Research downgraded shares of Marina Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, March 12th. Oppenheimer restated a “buy” rating on shares of Marina Biotech in a research report on Tuesday, March 19th. Finally, Piper Jaffray Companies raised their price objective on shares of Marina Biotech from $24.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, May 8th.
Several hedge funds have recently bought and sold shares of MRNA. Parallel Advisors LLC acquired a new position in shares of Marina Biotech during the 1st quarter worth approximately $207,000. Bainco International Investors acquired a new position in shares of Marina Biotech during the 1st quarter worth approximately $224,000. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Marina Biotech during the 1st quarter worth approximately $1,051,000.
Marina Biotech (OTCMKTS:MRNA) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.01). The company had revenue of $16.03 million for the quarter, compared to analysts’ expectations of $33.59 million.
Marina Biotech Company Profile
Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.
Further Reading: Using the New Google Finance Tool
Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.